Effect of Modified Erchentang on Expressions of Chemokine Receptor CXCR1/2 and CXCL8 in Patients with AECOPD

Li-zhi SHANG; Shu JI; Yao-yang LI; Meng-di MAO; Guo-qiang WANG; Long-tao SHI; Guang-yuan ZHANG; Li-li XU; Wen-ying XIE

doi:10.13422/j.cnki.syfjx.20192406

您当前的位置：

首页 >

文章列表页 >

Effect of Modified Erchentang on Expressions of Chemokine Receptor CXCR1/2 and CXCL8 in Patients with AECOPD

Classic Prescriptions | 更新时间：2021-02-09

- Effect of Modified Erchentang on Expressions of Chemokine Receptor CXCR1/2 and CXCL8 in Patients with AECOPD
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 25, Issue 24, Pages: 1-8(2019)
- 作者机构：
  
  河南中医药大学，郑州　 450046
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.20192406
  CLC： R2-0; R22; R285.5; R289
- Published：20 December 2019，
  
  Published Online：23 September 2019，
  
  Received：28 June 2019，
- 稿件说明：
扫描看全文
Li-zhi SHANG, Shu JI, Yao-yang LI, et al. Effect of Modified Erchentang on Expressions of Chemokine Receptor CXCR1/2 and CXCL8 in Patients with AECOPD. [J]. Chinese Journal of Experimental Traditional Medical Formulae 25(24):1-8(2019)
DOI：

Li-zhi SHANG, Shu JI, Yao-yang LI, et al. Effect of Modified Erchentang on Expressions of Chemokine Receptor CXCR1/2 and CXCL8 in Patients with AECOPD. [J]. Chinese Journal of Experimental Traditional Medical Formulae 25(24):1-8(2019) DOI： 10.13422/j.cnki.syfjx.20192406.

摘要

目的：

观察二陈汤加味对急性加重期慢性阻塞性肺疾病(AECOPD)患者CXC趋化因子配体8(CXCL8)及其受体CXCR1/2，巨噬细胞炎性蛋白2(MIP-2)蛋白表达的影响，评价二陈汤加味对AECOPD患者抗炎的作用与机制。

方法：

选取符合纳入标准的AECOPD患者200例，随机分成观察组和对照组各100例。2组均在西药治疗的基础上，对照组给予急支糖浆，观察组给予二陈汤加味，疗程14 d。酶联免疫吸附测定(ELISA)检测患者血浆中巨噬细胞炎性蛋白2(MIP-2)，CXCL8含量；蛋白免疫印迹法(Western blot)检测外周血单个核细胞(PBMCs)中CXCL8，CXCR1和CXCR2蛋白表达；免疫细胞化学染色检测PBMCs中CXCL8，CXCR1，CXCR2定位表达及阳性率。

结果：

治疗后观察组较同组治疗前血浆中CXCL8，MIP-2含量均显著减少(

0.05)，PBMCs中CXCL8，CXCR1，CXCR2蛋白表达均降低(

0.05，

0.01)。治疗后与对照组比较，观察组总有效率、肺FEV

均显著高于对照组(

0.05)，血浆MIP-2，CXCL8含量，CXCL8，CXCR1蛋白表达均显著低于对照组(

0.05)。

结论：

二陈汤加味对COPD有抗炎作用。其机制可能与下调CXCL8，CXCR1，CXCR2表达，减少CXCL8，MIP-2的合成与释放，抑制炎细胞的过多渗出与趋化，从而减轻炎症反应有关。

Abstract

Objective:

To observe the clinical efficacy of modified Erchentang on CXC chemokine ligand receptors (CXCR1/2)and their ligands CXCL8

macrophage inflammatory protein -2(MIP-2) in patients of chronic obstructive pulmonary disease(AECOPD)at acute exacerbation stage

and assess the effect and mechanism of modified Erchentang on anti-inflammatory in patients of AECOPD.

Method:

This study was a multicenter

randomized single blind

controlled trial. The authors selected 200 cases in conformity to the standards of AECOPD. The AECOPD patients were randomly divided into modified Erchentang group and control group. In addition to the western medicine

modified Erchentang was also given to the modified Erchentang group

and Jizhitangjiang was given to the control group for 14 days. Each group was observed for the alleviation of the symptoms. Euzyme-linked immunosorbent assay (ELISA) was used to determine the levels of CXCL8 and MIP-2 in the patients' plasma of all groups before and after treatment. Western blot were used to detect the levels of CXCR1

CXCR2 and CXCL8 protein in peripheral blood mononuclear cells(PBMCs). Immunocytochemistry (ICC) method was used to detect the expressions of CXCL8

CXCR1 and CXCR2 protein in PBMCs.

Result:

The level of CXCL8 in plasma

and the expressions of CXCR1

CXCR2 and CXCL8 mRNA and protein in the modified Erchentang group were decreased significantly than those in the control group(

0.05

0.01).

Conclusion:

Modified Erchentang has an anti-inflammatory effect on AECOPD. Its mechanism may be related to the down-regulation of the expressions of CXCL8

CXCR1 and CXCR2

the reduction of synthesis and release of CXCL8 and MIP-2

the inhibition of the chemotaxis and activity of inflammatory cells

and the prevention of inflammation progress.

关键词

慢性阻塞性肺疾病二陈汤外周血单个核细胞炎症趋化因子

Keywords

chronic obstructive pulmonary disease (COPD)Erchentangperipheral blood mononuclear cells (PBMCs)inflammationchemokine

references

Vestbo J, Hurd S S, Agusti A G, et al. Global strategy for the diagnosis, managerment, and prevention of chronic obstructive pumlonary disease: GOLD executive summary [J].Am J Respir Crit Care Med, 2013, 187(4): 347-365.

Vestbo J, Mathioudakis A G. The emerging Chinese COPD epidemic [J].Lancet, 2018, 391(10131): 1642-1643.

茅培英，崔德健，宋一平，等．大鼠吸入烟雾后支气管肺组织ICAM-1及中性粒细胞炎症因子的变化[J]．基础医学与临床，2001，21(3)：222-225．

Kim V, Cornwell W D, Oros M, et al. Plasma Chemokine signature correlates with lung goblet cell hyperplasia in smokers with and without chronic obstructive pulmonary disease [J].BMC Pulm Med, 2015, 111(1): 2-10.

Inui T, Watanabe M, Nakamoto K, et al. Bronchial epithelial cells produce CXCL1 in response to LPS and TNFα: a potential role in the pathogenesis of COPD [J].Exp Lung Res, 2018, 44(7): 323-331.

Henrot P, Prevel R, Berger P, et al. Chemokines in COPD: from implication to therapeutic use [J].Int J Mol Sci, 2019, 20(11): 2785.

O'Donnell R A, Peebles C, Ward J A, et al. Relationship between peripheral airway dysfunction, airway obstruction and neutrophilic inflammation in COPD [J].Thorax, 2004, 59(10): 837-842.

Ponce-Gallegos M A, Ramírez-Venegas A, Falfán-Valencia R. Th17 profile in COPD exacerbations [J].Int J Chron Obstruct Pulmon Dis, 2017, 22(12): 1857-1865.

谢文英，季书，尚立芝．二陈汤加味对COPD患者氧化应激、缺氧诱导因子1α及沉默信息调节因子1(Sirt1)的影响[J]．中国实验方剂学杂志，2017，23(10)：155-162．

陈四清，谢文英，尚立芝，等．二陈汤加味对慢性阻塞性肺疾病急性加重期老年患者免疫功能及CCL18、CC16、IL-8、sICAM-1的影响[J]．中国实验方剂学杂志，2017，23(10)：171-177．

中华医学会呼吸病学分会慢性阻塞性肺疾病学组．慢性阻塞性肺疾病诊治指南(2013年修订版)[J]．中华结核和呼吸杂志，2013，36(4)：255-264．

慢性阻塞性肺疾病急性加重(AECOPD)诊治专家组．慢性阻塞性肺疾病急性加重(AECOPD)诊治中国专家共识(2014年修订版)[J]．国际呼吸杂志，2014，34(1)：1-11．

中华人民共和国卫生部．中药新药临床研究指导原则[M]．北京：中国医药科技出版，2002：61．

中华中医药学会内科分会肺系病专业委员会．慢性阻塞性肺疾病中医证候诊断标准( 2011版)[J]．中医杂志，2012，53(2)：177-178．

尚立芝，季书，谢文英，等．二陈汤加味对COPD急性期患者CC16，SP-D及HAT/HDAC的影响[J]．中国实验方剂学杂志，2017，23(10)：163-170．

王辰．呼吸病学[M]．2版．北京：人民卫生出版社，2014：48-51．

Moermans C, Heinen V, Nguyen M, et al. Local and systemic cellu-lar inflammation and cytokine release in chronic obstructive pulmo-nary disease [J].Cytokine, 2011, 56(2): 298-304.

尚立芝，谢文英，张良芝，等．爱罗咳喘宁对稳定期和急性加重期COPD抗炎作用及机制研究[J]．中国实验方剂学杂志，2015，21(1)：134-139．

吴珂，尚立芝，谢文英，等．二陈汤加味对慢性阻塞性肺疾病细支气管壁细胞外基质重塑的影响[J]．中国实验方剂学杂志，2018，24(14)：122-127．

包永生，谢文英，王俊月，等．二陈汤加味对慢性阻塞性肺疾病大鼠肺组织GATA3，T-bet表达的影响[J]．中国实验方剂学杂志，2019，25(23)：19-25．

陈四清，季书，尚立芝，等．二陈汤加味对慢性阻塞性肺疾病大鼠转化生长因子-β1及组蛋白去乙酰化酶2基因表达的影响[J]．中国实验方剂学杂志，2017，23(10)：147-154．

Stillie R, Farooq S M, Gordon J R, et al. The functionalsignificance behind expressing two IL-8 receptor types on PMN [J].J Leukoc Biol, 2009, 86(3): 529-543.

Peveri P, Walz A, Dewald B, et al. A novel neutrophil-activating factor produced by human mononuclear phagocytes [J].J Exp Med, 1988, 167(5): 1547-1559.

Holmes W E, Lee J, KUANG W J, et al. Structure and functional expression of a human interleukin-8 receptor [J].J Immunol, 2009, 183(5): 2895-2897.

Vacchini A, Mortier A, Proost P, et al. Differential effects of posttranslational modifications of CXCL8/interleukin-8 on CXCR1 and CXCR2 internalization and signaling properties [J].Int J Mol Sci, 2018, 19(12): 3768.

Snelgrove R J. Targeting of a common receptor shared by CXCL8 and N-Ac-PGP as a therapeutic strategy to alleviate chronic neutrophilic lung diseases [J].Eur J Pharmacol, 2011, 667(1/3): 1-5.

Helen H, Bikash D, Nouri N. Role of the CXCL8-CXCR1/2 Axis in cancer and inflammatory diseases [J].Theranostics, 2017, 7(6): 1543-1588.

Belchamber K B R, Donnelly L E. Macrophage dysfunction in respiratory disease [J].Results Probl Cell Differ, 2017, 62: 299-313.

Pouwels S D, Hesse L, Faiz A, et al. Susceptibility for cigarette smoke-induced DAMP release and DAMP-induced inflammation in COPD [J].Am J Physiol Lung Cell Mol Physiol, 2016, 311(5): L881-L892.

Ha H, Debnath B, Neamati N. Role of the CXCL8-CXCR1/2 Axis in cancer and inflammatory diseases [J].Theranostics, 2017, 7(6): 1543-1588.

Kadowaki M, Yamada H, Sato K, et al. Extracellular acidification-induced CXCL8 production through a proton-sensing receptor OGR1 in human airway smooth muscle cells: a response inhibited by dexamethasone [J].J Inflamm (Lond), 2019, 16(4): 2-10.

徐绍娟，胡爱民．细菌性肺炎患者IL-6及IL-8及C反应蛋白的测定及其意义[J]．中国微生态学杂志，2015，27(6)：702-703．

Bertini R, Allegretti M, Bizzarri C, et al. Noncompetitiveallosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injury [J].Proc Natl Acad Sci USA, 2004, 101(32): 11791-11796.

March T H, Barr E B, Finch G L, et al. Effects of concurrentozone exposure on the pathogenesis of cigarette smoke induced emphysema in B6C3F1 mice [J].Inhal Toxicol, 2002, 14(12): 1187-1213.

Crul T, Spruit M A. Markers of inflammation and disuse in vastus lateralis of chronic obstructive pulmonary disease patients [J].Eur J Clin Invest, 2007, 11(37): 897-904.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Mechanism of Modified Erchentang on COPD Inflammation Based on TNF-α/TNFR1/RIPKs Pathway

Modified Erchentang Alleviates Inflammation in Chronic Obstructive Pulmonary Disease via Midkine/Notch2/Hey1 Signaling Pathway in Rats

Effect of Modified Erchentang on CC16, SP-D and HAT and HDAC in Patients at Acute Exacerbation Stage of COPD

Effect of Modified Erchentang on Hif-1 and Sirtuins 1 in Patients with COPD

Linggui Zhugantang Treats Chronic Bronchitis in Rats via PLA2-TRPV1/TRPA1 Pathway

Related Author

CHEN Zhuang

LIU Gaoyang

XIE Wenying

SHANG Lizhi

HU Wenhao

LI Yaoyang

LIU Gaoyang

CHEN Zhuang

Related Institution

Henan Provincial Second People's Hospital

School of Traditional Chinese Medicine， Beijing University of Chinese Medicine

Institute of Basic Theory for Chinese Medicine，China Academy of Chinese Medical Sciences

Institute for Brain Disorders，Beijing University of Chinese Medicine

West China School of Medicine，Sichuan University

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰